» Articles » PMID: 32134335

Prognostic Value of Cripto-1 Expression in Non-small-cell Lung Cancer Patients: a Systematic Review and Meta-analysis

Overview
Journal Biomark Med
Date 2020 Mar 6
PMID 32134335
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

This systematic review and meta-analysis aimed to analyze the association between cripto-1 expression and prognosis as well as clinicopathological features of non-small-cell lung cancer (NSCLC) patients. The electronic databases for all articles about NSCLC and cripto-1 expression were searched. Twelve articles were enrolled in this meta-analysis (3130 samples). In NSCLC patients, cripto-1 was expressed higher than in normal tissues. Cripto-1 expression was closely correlated with lymph node metastasis, histological differentiation and advanced clinical stage of NSCLC patients, but not related to smoking, age and gender. Pooled hazard ratios found that high cripto-1 expression had poor overall survival and progression-free survival. Cripto-1 could serve as a novel biomarker for predicting poor prognosis in NSCLC patients.

Citing Articles

A blood and bronchoalveolar lavage protein signature of rapid FEV decline in smoking-associated COPD.

DiLillo K, Norman K, Freeman C, Christenson S, Alexis N, Anderson W Sci Rep. 2023; 13(1):8228.

PMID: 37217548 PMC: 10203309. DOI: 10.1038/s41598-023-32216-0.


CRIPTO Is a Marker of Chemotherapy-Induced Stem Cell Expansion in Non-Small Cell Lung Cancer.

Francescangeli F, De Angelis M, Rossi R, Sette G, Eramo A, Boe A Front Oncol. 2022; 12:830873.

PMID: 35719935 PMC: 9200964. DOI: 10.3389/fonc.2022.830873.